The Ledger

Hospitals went back to federal court Friday to stop a federal drug-discount rebate program they say would cost them more than $1 billion a year just to run. The American Hospital Association (AHA), the Maine Hospital Association and four safety-net hospitals sued October 9 in the U.S. District Court for the District of Maine to block the revised 340B rebate pilot, which the Department of Health and Human Services (HHS) has scheduled for January 1, 2027. Under the 340B program, hospitals buy outpatient drugs at deep discounts; the pilot would have them pay full price and wait for a manufacturer rebate. AHA says hospital analyses put the added administrative cost above $1 billion a year, and says the revised program is twice the size of the 2025 version that the district court and the 1st Circuit faulted for ignoring hospital costs. For safety-net operators the exposure is cash flow, because rebate delays turn a discount into a receivable. Per Becker’s Hospital Review, the Health Resources and Services Administration (HRSA) approved 10 drugmakers and 21 drugs for the pilot October 1; this run could not open the HRSA notice, so that count is unconfirmed. Confidence: High on the filing, plaintiffs and cost claim (the cost figure is AHA’s estimate, not a court finding); Low on the drug count. Sources: AHA release on the October 9 suit. Supplemental: Becker’s Hospital Review.

UnitedHealth Group reports third-quarter results Tuesday at 8 a.m. Eastern, the first big insurer read of the week. The company lists an October 13 earnings call on its investor relations page. Operators and corp-dev teams will look at two lines: the medical care ratio, the share of premiums spent on care, and Medicare Advantage membership, after the Medicare Advantage Star Ratings reset the 2028 bonus picture last week. Texas Attorney General Ken Paxton also opened an investigation of the company around October 5 over care denials and issued civil investigative demands, per Healthcare Dive; the company did not comment in that report. This run did not open the Texas attorney general’s release. Consensus figures vary by source and are not repeated here. Confidence: High on the call time; Medium on the Texas probe. Sources: UnitedHealth Group investor relations. Supplemental: Healthcare Dive on the Texas probe.

The Federal Trade Commission (FTC) warned about two dozen hospital operators that incomplete price postings may violate consumer protection law, per Healthcare Dive. The letters went out around October 5 and the FTC did not name the recipients. It cited possible scrutiny from its antitrust arm and from HHS; no fine amount or response deadline was reported. This is a second enforcement track beside the Centers for Medicare and Medicaid Services (CMS), which Healthcare Dive says has fined 28 hospitals since 2021. For finance and compliance teams, the risk is that one posting error now has two possible regulators. Confidence: Medium. The primary source reviewed is the FTC’s template letter, not the signed letters. Sources: FTC warning letter template on hospital price transparency. Supplemental: Healthcare Dive.

Hospital operating margins ended June at 0.7 percent, the best month of 2026 so far, after starting the year negative, according to Strata Decision Technology. The October 7 Strata report covers the first half of 2026. Outpatient visits fell 7.5 percent in May, which Strata attributes to deferred elective services and notes is consistent with prior years, and inpatient gynecology volume fell 8 percent in the half as hysterectomies moved to outpatient settings. Inpatient breast health volume rose 17.2 percent. A 0.7 percent margin is thin enough that one payer dispute or one new administrative cost, like the 340B rebate burden above, can erase it. Confidence: High on the figures as Strata reports them; they come from its own client data, not a federal dataset. Sources: Strata Decision Technology release.

Independence Blue Cross agreed October 2 to pay $22.5 million to resolve False Claims Act allegations that it inflated Medicare Advantage diagnosis codes. The Department of Justice alleged the Philadelphia insurer had nurses review charts in a 2016 to 2020 program but did not investigate or withdraw inaccurate codes they found, while telling CMS its data was accurate. The plan did not admit wrongdoing, and the case began with a 2020 whistleblower complaint. The settlement is small against the Medicare Advantage market, but it adds to the pattern of risk adjustment cases that reach back four to ten years. Confidence: Medium. This run relied on Healthcare Dive’s summary and did not open the Justice Department release. Sources: Justice Department release. Supplemental: Healthcare Dive.

THE DEAL SHEET

No new transactions spotted in the last 24 hours (October 10 and 11, a weekend). One pending item is listed for completeness.